Rankings · Price against the business

Most free cash flow per dollar of price

Graded A or B, ranked by free cash flow over the last twelve months divided by market value. Banks and insurers are left out, and yields above 50% are treated as data problems rather than bargains.

125 companies meet this test

Figures as of November 15, 2026

#CompanyGradeFree cash flow yieldP/ERevenue growthMarket value
1GMABGenmab A/SB+35.7%3.34+18% a year$3.2B
2NRIXNURIX THERAPEUTICS, INC.A+21.9%6.73—$1.7B
3BCRXBIOCRYST PHARMACEUTICALS, INC.B18.7%—+45% a year$2B
4HRMYHARMONY BIOSCIENCES HOLDINGS, INC.B+17.5%11.14+22% a year$2B
5TAKTakeda Pharmaceutical Company LimitedA16.0%50.12+3% a year$34.4B

More rankings

A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.